Author:
Gao Likun,Wang Zhi,Lu Danhua,Huang Jinling,Liu Jin,Hong Li
Funder
National Natural Science Foundation of China
Natural Science Foundation of Hubei Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference46 articles.
1. Haas, N. B. et al. Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma. Clin. Cancer Res. 25, 2080–2087 (2019).
2. Torre, L. A. et al. Ovarian cancer statistics, 2018. CA: A Cancer J. Clin. 68, 284–296 (2018).
3. Wright, J. D. et al. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet. Gynecol. 125, 1345–1352 (2015).
4. Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).
5. Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: A Cancer J. Clin. 69, 280–304 (2019).
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献